Changes at Mission Control notwithstanding, the new Cancer Moonshot is ready for liftoff, says Danielle Carnival, coordinator of the White House cancer initiative.
On Feb. 1, as President Joe Biden was preparing to fire up the Cancer Moonshot, Eric Lander was the scientist in charge of mission control.
Congress has extended FY22 spending talks once again, leaving the proposed Advanced Research Projects Agency for Health (ARPA-H)—a key piece of President Joe Biden’s cancer agenda—in limbo.
President Biden has been describing the Advanced Research Projects Agency for Health (ARPA-H), a DARPA-like biomedical research agency, as the centerpiece of his effort to “end cancer as we know it.”
A House appropriations subcommittee voted to increase NIH’s FY2022 budget by $6.5 billion—to $46.43 billion—which falls $2.5 billion short of President Joe Biden’s request for NIH.
The Advanced Research Projects Agency for Health, the centerpiece of the Biden Administration’s war on disease, is designed to be something much more than an ordinary federal bureaucracy.
President Joe Biden is requesting $52 billion in FY2022 for NIH—$9 billion above the enacted FY21 level—of which $6.5 billion is slated for the proposed Advanced Research Projects Agency for Health.
In an expression of support for increasing funding for cancer research and prevention, the Bidens earlier this week endorsed the National Cancer Research Month.
In his first address to a joint session of Congress April 28, President Joe Biden made a pitch for significantly increasing federal funding for biomedical research, especially cancer research—a cornerstone of his jobs plan.
The boundary between basic science and engineering has been the subject of animated discussions in cancer research for quite some time. Where does science end and engineering begin? Is that boundary porous? How does it shift over time?
